Back to School: How biopharma can reboot drug development. Access exclusive analysis here
Kinex granted Zenith marketing rights to cancer candidates Oraxol and Oratecan in Australia and New Zealand. Oraxol is
Sign in to your BioCentury account to access your content.
Get a two-week free trial subscription to BioCentury